Fundraising Fox
Allarity Therapeutics
NASDAQ: ALLRCambridge, US · Founded 2021 · Delaware corporation
Find your way into Allarity Therapeutics
Sign up to see every warm intro you have to Allarity Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Allarity Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allarity Therapeutics is a clinical-stage precision medicine company that uses its proprietary Drug Response Predictor technology to match cancer patients with therapies tailored to their disease. The company develops oncology drugs for difficult-to-treat cancers and is focused on improving patient outcomes through personalized treatment approaches.
Founders & leadership
Allarity Therapeutics was founded in 2021 by Steen Knudsen.
SK
Steen KnudsenFounderSteen Knudsen brings three decades of experience in bioinformatics and cancer research, including work in gene expression analysis, clinical trials, and biomarker development. He has held roles in medical device development, quality systems, regulatory affairs with the FDA, and global patent strategy.
JG
James G. CullemBoard Director2022–2024James G. Cullem is Senior Vice President of Corporate Development and Secretary at Allarity Therapeutics, a clinical-stage precision medicine company developing oncology treatments. He has held leadership roles in biotechnology operations, business development, capital fundraising, and strategic planning across multiple early-stage life sciences companies.
SC
Steve CarchediChief Executive Officer, President and Director2019–2022Steve Carchedi is President and CEO of Allarity Therapeutics, a clinical-stage precision medicine company developing oncology drugs. He brings over 25 years of pharmaceutical industry experience across roles at Johnson & Johnson, General Electric, Eli Lilly, Bristol Myers Squibb, and Endo Pharmaceuticals, with expertise in oncology, neurology, medical diagnostics, and commercial operations including P&L management for businesses ranging from $100 million to over $1 billion.
JE
Jens Erik KnudsenTreasurer and CFO
Reported raises · per SEC filings
Form D private placements$26.9M disclosed across 6 rounds · 2021–2024
▶$400KraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
▶$400KraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas JensenExecutive Officer, Director
- Gerald McLaughlinDirector
- Laura BenjaminDirector
- Joan BrownExecutive Officer
- Joseph VazzanoDirector
- Offering amount
- $1.4M
- Amount sold
- $400K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.6MraisedSep 2023 · 2 investors · BiotechnologyRule 506(b)
▶$1.6MraisedSep 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald McLaughlinDirector
- James CullemExecutive Officer, Director
- Joseph VazzanoDirector
- Laura BenjaminDirector
- Joan BrownExecutive Officer
- Thomas JensenDirector
- Amount sold
- $1.6M
- Sales commissions
- $170.7K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3.4MraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.4MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James G. CullemExecutive Officer, Director
- Gerald McLaughlinDirector
- Steen KnudsenExecutive Officer
- Marie FoeghExecutive Officer
- David A. RothDirector
- Thomas JensenExecutive Officer, Director
- Joan BrownExecutive Officer
- Amount sold
- $3.4M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$350KraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$350KraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald McLaughlinDirector
- Steen KnudsenExecutive Officer
- Thomas JensenExecutive Officer, Director
- David A. RothDirector
- Marie FoeghExecutive Officer
- Joan BrownExecutive Officer
- James G. CullemExecutive Officer, Director
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.2MraisedMar 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMar 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James G. CullemExecutive Officer, Director
- Gerald McLaughlinDirector
- Thomas JensenDirector
- Joan BrownExecutive Officer
- David A. RothDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$20MraisedMay 2021 · 1 investors · BiotechnologyRule 506(b)
▶$20MraisedMay 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James G. CullemExecutive Officer
- Steve CarchediExecutive Officer, Director
- Jens Erik KnudsenExecutive Officer
- Offering amount
- $40M
- Amount sold
- $20M
- Sales commissions
- $1.5M
- Placement agents
- LifeSci Capital LLC
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
Vested FinanceVested Finance is an investment platform that lets Indian residents and NRIs invest in over 10,000 US stocks and ETFs, including full and fractional shares. Securities are offered through VF Securities Inc. with brokerage execution handled by partner DriveWealth.
Companies working in the same space as Allarity Therapeutics.
Frequently asked questions
- What does Allarity Therapeutics do?
- Allarity Therapeutics is a clinical-stage precision medicine company that uses its proprietary Drug Response Predictor technology to match cancer patients with therapies tailored to their disease. The company develops oncology drugs for difficult-to-treat cancers and is focused on improving patient outcomes through personalized treatment approaches.
- Who founded Allarity Therapeutics?
- Allarity Therapeutics was founded by Steen Knudsen in 2021.
- How much funding has Allarity Therapeutics raised?
- Allarity Therapeutics has disclosed $26.9M raised across 6 rounds.
- Where is Allarity Therapeutics headquartered?
- Allarity Therapeutics is headquartered in Cambridge, US.